Holen Sie sich die Stockscreener-App
2.895
1.76%
0.055
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.84
Offen:
$2.84
24-Stunden-Volumen:
802.57K
Relative Volume:
0.12
Marktkapitalisierung:
$583.70M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-1.3656
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
+6.65%
1M Leistung:
+9.06%
6M Leistung:
+189.18%
1J Leistung:
+41.67%
1-Tages-Spanne:
$2.80
$2.93
1-Wochen-Bereich:
$2.73
$3.11
52-Wochen-Spanne:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Vergleichen Sie ESPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.895 | 657.81M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
143.22 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.45 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.195 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.12 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
449.15 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Why analysts remain bullish on Esperion Therapeutics Inc. stockWeekly Loss Report & Real-Time Volume Analysis - newser.com
Can volume confirm reversal in Esperion Therapeutics Inc.July 2025 Intraday Action & Verified Swing Trading Watchlists - newser.com
Is Esperion Therapeutics Inc. stock reversal real or fake2025 Market WrapUp & Accurate Buy Signal Alerts - newser.com
Multi asset correlation models including Esperion Therapeutics Inc.July 2025 Drop Watch & Growth Focused Stock Reports - newser.com
Esperion Therapeutics (ESPR) to Release Quarterly Earnings on Thursday - MarketBeat
Can Esperion Therapeutics Inc. stock deliver surprise earnings beat2025 Technical Patterns & Safe Capital Preservation Plans - newser.com
Will Esperion Therapeutics Inc. (0ET) stock benefit from mergersEarnings Growth Summary & Low Drawdown Investment Ideas - newser.com
Why analysts raise outlook for Esperion Therapeutics Inc. (0ET) stockMarket Activity Report & Free Technical Confirmation Trade Alerts - newser.com
Relative strength of Esperion Therapeutics Inc. in sector analysisEarnings Growth Report & Risk Controlled Daily Plans - newser.com
Smart tools for monitoring Esperion Therapeutics Inc.’s price action2025 Market Trends & Technical Buy Zone Confirmation - newser.com
Will earnings trigger a reversal in Esperion Therapeutics Inc.2025 Big Picture & Technical Entry and Exit Alerts - newser.com
Using AI based signals to follow Esperion Therapeutics Inc.Portfolio Growth Summary & Fast Gaining Stock Strategy Reports - newser.com
How high can Esperion Therapeutics Inc. stock go2025 Earnings Surprises & Risk Adjusted Buy/Sell Alerts - newser.com
Why Esperion Therapeutics Inc. stock is favored by top institutionsGDP Growth & Verified High Yield Trade Plans - newser.com
Published on: 2025-10-30 01:22:55 - newser.com
Identifying reversal signals in Esperion Therapeutics Inc.Quarterly Trade Summary & Low Drawdown Trading Strategies - newser.com
Applying Elliott Wave Theory to Esperion Therapeutics Inc.Quarterly Market Review & Community Consensus Trade Signals - newser.com
Why Esperion Therapeutics Inc. is moving todayEarnings Miss & Weekly High Conviction Trade Ideas - newser.com
Esperion Therapeutics (NASDAQ:ESPR) Trading 7.1% HigherTime to Buy? - MarketBeat
How to integrate Esperion Therapeutics Inc. into portfolio analysis toolsWeekly Volume Report & Step-by-Step Swing Trade Plans - newser.com
Published on: 2025-10-28 23:56:41 - newser.com
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET. - The Manila Times
How Esperion Therapeutics Inc. stock benefits from global expansion2025 Technical Patterns & Fast Entry High Yield Tips - newser.com
Esperion (NASDAQ: ESPR) sets Nov. 11, 2 p.m. ET KOL webinar on statin intolerance - Stock Titan
Will Esperion Therapeutics Inc. stock return to pre crisis levelsWeekly Gains Summary & High Conviction Buy Zone Picks - newser.com
Can Esperion Therapeutics Inc. stock reach $100 price targetPortfolio Risk Summary & Technical Pattern Alert System - newser.com
Will Esperion Therapeutics Inc. stock gain from lower inflation2025 Performance Recap & Risk Managed Trade Strategies - newser.com
How to use Fibonacci retracement on Esperion Therapeutics Inc.Quarterly Trade Summary & Real-Time Sentiment Analysis - newser.com
Should you wait for a breakout in Esperion Therapeutics Inc.Earnings Recap Summary & AI Driven Stock Movement Reports - newser.com
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):